Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR | Market Cap | 2.84M |
| Revenue (ttm) | 17.53M |
| Net Income (ttm) | -9.30M |
| Shares Out | 13.50M |
| EPS (ttm) | -32.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 137,269 |
| Average Volume | 421,480 |
| Open | 0.2021 |
| Previous Close | 0.2090 |
| Day's Range | 0.2021 - 0.2149 |
| 52-Week Range | 0.2000 - 15.3000 |
| Beta | 0.03 |
| RSI | 24.04 |
| Earnings Date | Sep 11, 2025 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. Its accessories comprise HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; K5 tracer, a solution to perform continuous scanning of 3D surfaces; pushbutton panels; XPower digital drives for axis and spindle movement; and... [Read more]
Financial Performance
In 2024, Fidia's revenue was 17.53 million, a decrease of -38.98% compared to the previous year's 28.74 million. Losses were -9.30 million, 611.4% more than in 2023.
Financial StatementsNews
Dr. Gottlieb on China's biotech strategy: China has become very adept at following U.S. discoveries
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss China's biotech strategy, how China is gaining ground on the U.S. in the biotech sector, and more.
Animal Testing, Human-Based Models, and Artificial Intelligence
Dear reader, in a groundbreaking move, the U.S. Food and Drug Administration (FDA) recently announced significant changes to its policies concerning preclinical drug testing. The a...
Lupin shares edge higher after tentative US FDA approval for HIV drug generic
Shares of Lupin Ltd edged up on Thursday, September 25, trading 1.34% higher at ₹2,017.50 apiece, after the company announced a key regulatory milestone. The global pharma major has received tentative...
uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond
uniQure achieved a 75% statistically significant slowing of Huntington's Disease progression with AMT-130 in a pivotal phase 1/2 study. Read why QURE is a Strong Buy.
FDA busts Pardi unit using bleaching agent to whiten rasgullas
Nagpur: The Food and Drug Administration (FDA) vigilance wing seized 1,200 kg of adulterated rasgulla worth Rs1.93 lakh, 2,500 kg of curd worth Rs50,0.
BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL
FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.
AstraZeneca (AZN) Receives FDA Priority Review for Enhertu
AstraZeneca (AZN) Receives FDA Priority Review for Enhertu
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.
NRx Pharmaceuticals gets FDA approval for suitability petition of Ketafree
NRx Pharmaceuticals gets FDA approval to advance Ketafree, a preservative-free ketamine product. Read more here.
NRXP Advances with FDA Support for Preservative-Free Ketamine Product
NRXP Advances with FDA Support for Preservative-Free Ketamine Product
AstraZeneca, Daiichi Sankyo under priority review of FDA for breast cancer
Merck CEO Rob Davis on FDA approval of Keytruda injection, navigating new vaccine landscape
CNBCs Angelica Peebles and Merck chairman and CEO Rob Davis join 'Squawk Box' to discuss the FDA's approval of the injectable version of Keytruda, pricing for the new injection, navigating the new vac...
Watch CNBC's full interview with Merck chairman and CEO Rob Davis
CNBCs Angelica Peebles and Merck chairman and CEO Rob Davis join 'Squawk Box' to discuss the FDA's approval of the injectable version of Keytruda, pricing for the new injection, navigating the new vac...
Biogen (BIIB) Faces Minor Setback with FDA Response on Spinraza Dosage
Biogen (BIIB) Faces Minor Setback with FDA Response on Spinraza Dosage
Panic over counter: Delhi doctor's allay fears amid Donald Trump's Tylenol warning; urge calm after FDA advisory
South Asian University's mess restricted non-vegetarian food during Navratri, sparking debate over inclusivity. Meanwhile, President Trump's warning against Tylenol use during pregnancy, linking it to...
FDA Requests Addl. Technical Info For Biogen's High-Dose Nusinersen Application For SMA Treatment
(RTTNews) - Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its supplemental New Drug Application or sNDA seeking ...
HeartFlow (HTFL) Stock Surges on FDA Approval
HeartFlow (HTFL) Stock Surges on FDA Approval
FDA Rejects Biogen's Application for Higher Spinraza Dose (BIIB)
FDA Rejects Biogen's Application for Higher Spinraza Dose (BIIB)
Why HeartFlow Stock Rocketed 14% Higher Today
Key PointsThe cardiac health specialist announced FDA approval for one of its diagnostic products.
Biogen (BIIB) Faces FDA Setback on High Dose Nusinersen Application
Biogen (BIIB) Faces FDA Setback on High Dose Nusinersen Application
FDA initiates label change on Tylenol to warn of autism
The Food and Drug Administration (FDA) announced Monday it has begun the process of changing the labeling on acetaminophen to suggest that it may cause autism and ADHD in children whose mothers took t...
Biogen gets complete response letter from FDA for higher dose Spinraza
Trump claims paracetamol use in pregnancy raises autism risk in children
In the footage, Mr Trump said the Food and Drug Administration (FDA) was preparing new guidance on the use of paracetamol in pregnancy The post Trump claims paracetamol use in pregnancy raises autism ...
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal
Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
FDA cites Catalent Indiana issues in Scholar ... Full story available on Benzinga.com